FDA Section 361 vs 351 Allograft Compliance Guide

Under Title 21 of the Code of Federal Regulations (21 CFR Part 1271), human cells, tissues, and cellular and tissue-based products (HCT/Ps) are classified under either Section 361 or Section 351 of the Public Health Service (PHS) Act. Section 361 HCT/Ps are regulated solely to prevent infectious disease transmission and do not require pre-market approval, provided they meet strict criteria regarding minimal manipulation and homologous use. In contrast, Section 351 products are classified as biologics, drugs, or medical devices requiring full FDA pre-market approval, clinical trial data, and Biologics License Applications (BLAs).

Regulatory Overview: Title 21 CFR Part 1271 Framework

For medical practice managers, administrators, and clinical directors, navigating the regulatory oversight of human tissue allografts is vital to maintaining institutional compliance and safeguarding patient safety. The United States Food and Drug Administration (FDA) regulates human cells, tissues, and cellular and tissue-based products under a tiered risk-based framework set forth in 21 CFR Part 1271.

The regulatory pathway dictates how an allograft can be processed, labeled, marketed, and utilized clinically. Understanding the boundary between Section 361 HCT/Ps and Section 351 biological products is essential when procuring biologics for clinical integration.

What is a Section 361 HCT/P?

Section 361 of the PHS Act applies to tissues that meet four specific criteria established by the FDA. Products meeting these standards are governed under 21 CFR 1271 Subparts A through D. They do not require pre-market approval, Investigational New Drug (IND) applications, or BLA clearance prior to commercial distribution. Instead, manufacturers must register their facilities with the FDA, list their products, and strictly adhere to Current Good Tissue Practice (cGTP) to control communicable disease transmission risks.

What is a Section 351 Biologic?

If an HCT/P fails to meet any one of the four criteria under Section 361, it is automatically categorized as a Section 351 product. Section 351 allografts are regulated as biological drugs or medical devices. To be legally marketed, a Section 351 product must undergo extensive clinical trials, demonstrate safety and efficacy, and receive formal FDA approval via a Biologics License Application or Premarket Approval (PMA).

Core Criteria Distinguishing Section 361 vs Section 351 Allografts

The FDA evaluates tissue products using four primary legal benchmarks. Failing to satisfy any single baseline shifts an allograft from Section 361 oversight into the rigorous Section 351 regulatory pathway.

1. Minimal Manipulation Standard

The definition of minimal manipulation depends on whether the tissue is structural or non-structural in nature:

• Structural tissue: Processing must not alter the original relevant characteristics of the tissue relating to its utility for reconstruction, repair, or replacement. Examples include bone, skin, tendons, and structural umbilical cord or amniotic membrane allografts.
• Non-structural tissue: Processing must not alter the relevant biological characteristics related to the tissue's inherent biological functions. Examples include hematopoietic stem cells or cellular concentrates.

If a tissue processing method uses chemical digestion, enzymatic isolation, or extensive structural degradation to extract specific cell populations, the FDA considers the product more than minimally manipulated, placing it under Section 351 oversight.

2. Homologous Use Requirement

Homologous use is defined as the repair, reconstruction, replacement, or supplementation of a recipient's cells or tissues with an HCT/P that performs the same basic function in the recipient as in the donor.

For example, using an amniotic membrane allograft as a wound cover or barrier layer aligns with homologous use. However, administering a structural tissue allograft intravenously or promoting it for systemic, neurological, or organ-level regeneration falls outside homologous use and triggers Section 351 classification.

3. Combination with Synthetics or Drugs

A Section 361 HCT/P cannot be combined with another drug, biologic, or synthetic medical device, except for authorized water, crystalloids, or sterilizing and preserving agents that do not raise new safety concerns. Adding growth factors, synthetic scaffolds, or active pharmaceuticals automatically reclassifies the product under Section 351.

4. Systemic Effect and Metabolic Dependency

To qualify under Section 361, the tissue must not depend on the metabolic activity of living cells for its primary function, unless the tissue is for autologous use, allogeneic use in first- or second-degree blood relatives, or reproductive use. Products that rely on systemic absorption of viable living cells to achieve their clinical intention are regulated under Section 351.

Section 361 vs Section 351 Compliance Checklist for Practice Managers

Practice administrators must verify that all tissue products procured for clinical use match their appropriate regulatory classification. Utilizing non-compliant tissue products exposes practices to severe legal, regulatory, and financial liability.

• Verify FDA Facility Registration: Ensure the tissue bank or manufacturer has an active FDA establishment registration under 21 CFR 1271 and an unannounced inspection history free from severe FDA Form 483 observations or Warning Letters.
• Review Manufacturer Technical Files: Confirm that product labeling and package inserts explicitly outline the structural or non-structural nature of the tissue and state a compliant intended use.
• Audit Marketing and Clinical Claims: Audit vendor marketing materials and internal clinical communications. Claims of treating systemic diseases, anti-aging benefits, or organ repair cross into Section 351 drug claims.
• Validate cGTP Compliance: Verify donor screening processes, communicable disease testing protocols, and tissue processing logs provided by the supplier.
• Inspect Procurement Supply Chain: Work exclusively with established medical distributors who provide full lot traceability, chain-of-custody documentation, and clear regulatory verification for all tissue products.

Operational vs Clinical Considerations: Risk, Cost, and Governance

Regulatory compliance requires alignment between administrative management and clinical leadership. Both operational and clinical stakeholders face distinct risks when managing allograft integration.

Operational and Administrative Perspective

From an operational standpoint, practice managers must evaluate vendor viability, supply chain consistency, liability exposure, and regulatory exposure. Purchasing an unauthorized Section 351 product exposes the practice to vendor supply disruptions, FDA untitled warning letters, insurance audits, and potential medical malpractice coverage exclusions.

Administrators working with pain management doctors or orthopedists must ensure that tissue product costs align with practice overhead while maintaining absolute compliance with state medical boards and federal oversight bodies.

Clinical and Governance Perspective

Clinical directors must ensure that tissue allografts are applied strictly within their designated scope of homologous use. Physicians must rely on verified structural mechanism of action rather than non-compliant claims regarding cellular viability or metabolic systemic action. Maintaining clear clinical notes detailing the structural rationale for tissue application safeguards both patient care and practice integrity.

For detailed answers on compliance documentation and regulatory definitions, practice teams can consult our frequently asked questions resource.

What This Means for Your Practice: Concrete Next Steps

To maintain an audit-ready practice that prioritizes clinical outcomes and regulatory compliance, take the following actions:

1. Conduct an Internal Allograft Audit: Review every human tissue product currently stocked in your clinical inventory. Match product package inserts against intended clinical usage.
2. Request Vendor Regulatory Validation Packets: Demand comprehensive compliance documentation from every tissue vendor, including FDA registration numbers, cGTP summaries, and homologous use rationale statements.
3. Refine Clinical Documentation Templates: Update Electronic Health Record (EHR) templates to document the precise structural application and homologous rationale for each allograft procedure.
4. Standardize Staff Training: Train clinical and front-office personnel on approved terminology to ensure marketing and clinical discussions remain within compliant Section 361 boundaries.

Partnering with Compliant Biologics Distributors

At Dallas Regenerative Solutions, we assist clinical teams and practice managers across Texas and nationwide in navigating complex regulatory landscapes. Learn more about Dallas Regenerative Solutions and how our strict sourcing standards ensure compliant tissue procurement.

To evaluate your current tissue allograft procurement or explore compliant biologics options for your practice, contact our team today for a professional consultation.